1 min read
Akebia Receives $60 Million Initial Tranche Under $140 Million Facility
The company can request another $80 million, subject to Symbiotic Capital’s discretion.

Akebia Therapeutics, Inc. announced Monday that it received $60 million as the initial funding under a senior secured term loan facility with Symbiotic Capital. The facility can total up to $140 million, including the initial tranche.
Akebia may request another $80 million under the arrangement. That additional funding is subject to Symbiotic’s discretion, so the maximum facility amount does not mean the full $140 million has been provided.
The announcement identifies Symbiotic Capital as the lender and describes the financing as a senior secured term loan. Any further funding would depend on the lender’s decision.